We are live on ! Find out more
ENVB icon

Enveric Biosciences
ENVB

13 hedge funds and large institutions have $337K invested in Enveric Biosciences in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

10% more capital invested

Capital invested by funds: $307K → $337K (+$29.9K)

0.01% more ownership

Funds ownership: 0.04% → 0.04% (+0.01%)

0% more funds holding

Funds holding: 13 → 13 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$88.6K
2
AI
AdvisorShares Investments
Maryland
+$25.6K
3
TSS
Two Sigma Securities
New York
+$7.82K
4
Two Sigma Investments
Two Sigma Investments
New York
+$6.81K
5
Citadel Advisors
Citadel Advisors
Florida
+$6.53K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$21.9K
2
BlackRock
BlackRock
New York
-$10.5K
3
HF
HRT Financial
New York
-$6K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$74
5
MG
Mather Group
Illinois
-$8
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
AdvisorShares Investments
Maryland
$174K +$25.6K +278 +16%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$103K +$88.6K +963 +388%
TSS
3
Two Sigma Securities
New York
$14.5K +$7.82K +85 +100%
VF
4
Virtu Financial
New York
$11K +$4.69K +51 +66%
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.63K – – –
TRCT
6
Tower Research Capital (TRC)
New York
$8.23K +$3.04K +33 +52%
Two Sigma Investments
7
Two Sigma Investments
New York
$6.34K +$6.81K +74 New
Citadel Advisors
8
Citadel Advisors
Florida
$6.04K +$6.53K +71 New
BlackRock
9
BlackRock
New York
$4.27K -$10.5K -114 -70%
UBS Group
10
UBS Group
Switzerland
$346 -$21.9K -238 -98%
Osaic Holdings
11
Osaic Holdings
Arizona
$271 – – –
Group One Trading
12
Group One Trading
Illinois
$129 – – –
Bank of America
13
Bank of America
North Carolina
$82 – – –
National Bank of Canada
14
National Bank of Canada
Quebec, Canada
$34 – – –
AWM
15
Avior Wealth Management
Nebraska
$23 – – –
Wells Fargo
16
Wells Fargo
California
$8 – – –
HF
17
HRT Financial
New York
– -$6K -61 Closed
Fidelity Investments
18
Fidelity Investments
Massachusetts
– -$74 -1 Closed
MG
19
Mather Group
Illinois
– -$8 – –
OP
20
ORG Partners
Indiana
– -$5 – –

ENVB Hedge Fund Activity: Q3 2024 in Review

13 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q3 2024, worth a combined $337K — up 9.7% from $307K a quarter earlier.

Fund positioning in ENVB was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 5 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $88.6K. The largest seller was UBS Group, cutting an estimated $21.9K.

  • 13 institutional investors held Enveric Biosciences (ENVB) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $337K of Enveric Biosciences stock for Q3 2024, up 9.7% quarter-over-quarter.
  • 2 funds opened new Enveric Biosciences positions in Q3 2024 and 2 closed out, a net change of 0 holders.
  • The largest Enveric Biosciences buyer in Q3 2024 was Geode Capital Management, an estimated $88.6K added.
  • The largest Enveric Biosciences seller in Q3 2024 was UBS Group, an estimated $21.9K sold.

Based on aggregated 13F filings for Q3 2024.